Pro drugs of PDE10 compounds
AssigneeMerck Sharp & Dohme Corp.
InventorsSachin Mittal, Jason W. Skudlarek, Izzat T. Raheem
Life of this patent
Estimating the term…
Abstract
The present invention is directed to pro drugs of 2-methyl-N-((5-methyl-1,3,4-thiadiazol-2-yl)methyl)-6-(((1S,2S)-2-(5-methylpyridin-2-yl)cyclopropyl)methoxy)pyrimidin-4-amine which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Claims3
A compound of structural Formula I:
- or pharmaceutically acceptable salt thereof, wherein:
- R1 is —C(O)OC1-6 alkyl, said alkyl optionally substituted with 1 to 3 groups of Ra, wherein the C1-6 alkyl of —C(O)OC1-6 alkyl is not t-butyl;
- and
- Ra is independently selected from the group consisting of C1-6 alkyl, OC1-6 alkyl, oxo, and halogen.
Dependencies are inferred from the claim text.